Top-News
Pharmazeutika USA

Sangamo Therapeutics Inc News

Aktie
WKN:  936386 ISIN:  US8006771062 US-Symbol:  SGMO
0,6399 €
+0,0456 €
+7,67%
14:10:25 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
177,35 Mio.
Marktkapitalisierung *
106,00 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 07.03.2024

Sangamo Therapeutics Inc News

09.05.24 - Businesswire
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
09.05.24 - Businesswire
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-​clinical data showcasing its novel next-​generation integrase technology ...
02.05.24 - Businesswire
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results ...
22.04.24 - Businesswire
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 ...
22.03.24 - Businesswire
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, ...
13.03.24 - Businesswire
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, ...
13.03.24 - Businesswire
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preclinical data from its proprietary adeno-​associated virus (AAV) capsid variant, ...
12.03.24 - Businesswire
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 ...
27.02.23 - PR Newswire
Thinking about buying stock in Broadmark Realty Capital, Seagen, Sangamo Therapeutics, Li Auto, or Bed Bath & Beyond?
Thinking about buying stock in Broadmark Realty Capital, Seagen, Sangamo Therapeutics, Li Auto, or Bed Bath & Beyond? PR Newswire
20.09.21 - Der Aktionär
Faule Äpfel im Korb: Die schlechtesten Empfehlungen aus dem Chart‑Check
28.12.20 - Der Aktionär
Sangamo: Favorit für 2021 nicht zu bremsen – 50 Prozent in wenigen Tagen
11.12.20 - Der Aktionär
Gen‑Schere‑Aktien Intellia, Editas Medicine und Co drehen durch: Sangamo schießt 53 Prozent nach oben
19.03.20 - Aktiencheck
Sangamo BioSciences: Mega-Deal mit Biogen und Pipeline-Fortschritte lassen die Aktie kalt - Aktienanalyse
Kulmbach (www.aktiencheck.de) - Sangamo BioSciences-​Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen ...
19.03.20 - Der Aktionär
Gilead‑Partner Sangamo: CEO Sandy Macrae wirft einen Blick in die Zukunft
09.03.20 - Der Aktionär
Sangamo: Top‑Deal für Gen‑Schere‑Hoffnung
09.03.20 - Aktiencheck
Sangamo BioSciences: Hochinteressante, aber spekulative Depotbeimischung - Aktienanalyse
Kulmbach (www.aktiencheck.de) - Sangamo BioSciences-​Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen ...
08.03.20 - Der Aktionär
Sangamo‑CEO zum Biogen‑Deal: "Immenses Potenzial"
28.02.20 - Aktiencheck
Sangamo BioSciences: Deal mit Biogen! Aktienanalyse
Kulmbach (www.aktiencheck.de) - Sangamo BioSciences-​Aktienanalyse von "Der Aktionär": Marion Schlegel vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen ...
28.02.20 - Der Aktionär
Hammermeldung: US‑Biotech Sangamo mit gewaltigem Kurssprung – was ist da los?
13.12.19 - Der Aktionär
Sangamo: So geht es jetzt beim heißen Biotech‑Eisen weiter – CMO im Exklusiv‑Interview

Newssuche

Videos

newspaper
17.05.24 +5,10%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »